Our study also suggests cancer stemness and Wnt/β-catenin signaling as factors contributing to the impaired sensitivity of mutant p53-harboring colon cancer cells to OX which may have therapeutic value for treating colon cancers with OX in future. The gene discussed is TP53; the disease is malignant colon neoplasm.